Skip to main content
main-content

01.12.2012 | Case report | Ausgabe 1/2012 Open Access

Journal of Medical Case Reports 1/2012

Vocal cord palsy after vincristine treatment in a child and the inefficacy of glutamic acid in the prevention of relapse: a case report

Zeitschrift:
Journal of Medical Case Reports > Ausgabe 1/2012
Autoren:
Piero Farruggia, Serena Tropia, Sonia Cannella, Giuseppa Bruno, Gaspare Oddo, Paolo D’Angelo
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1752-1947-6-128) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

PF made substantial contributions to the structure of the manuscript, was involved in clinical management of our patient and drafted the manuscript. ST was involved in clinical management and helped draft the manuscript. SC and GB analyzed and interpreted patient data regarding disease. GO was involved in pharmaceutical management of the disease, and participated in drafting part of the manuscript. PD made substantial contributions to the structure of the manuscript, was involved in clinical management of our patient, and was a major contributor in writing the manuscript. All authors read and approved the final manuscript.

Introduction

Vinca alkaloids have a proven role in the treatment of hematological neoplasms. The basis of their action as mitotic inhibitors is binding to microtubule proteins, but they may cause axonal degeneration. In some cases, it is likely a role in the onset of neurotoxicity can be related to pre-existing liver dysfunction or concomitant use of drugs such as itraconazole, phenytoin, isoniazid, erythromycin, azoles or allopurinol. Rarely, vincristine (VCR) can produce vocal cord palsy (VCP) as a consequence of peripheral neurotoxicity involving cranial nerves, a potentially life-threatening event.

Case presentation

A Caucasian 18-month-old girl, born to an Italian family and raised in Italy, with a high-risk acute lymphoblastic leukemia (ALL) was being treated according to the AIEOP-BFM ALL 2000 protocol. After the third dose of VCR (1.5 mg/m2) she developed isolated hoarseness, but stridor appeared soon after the fourth dose of VCR (last dose of induction phase). A flexible fiber-optic endoscope study showed a bilateral VCP (Figure 1). Electromyography revealed a predominantly axonal motor neuropathy involving above the lower extremities. A nerve conduction study of the larynx was not performed because the association of VCR administration with significant respiratory symptoms and immobility of the vocal folds, clearly shown by the fiber-optic endoscope, allowed us to make a definite diagnosis. No side effects of VCR other than VCP were found. Her stridor started to improve within the first seven days and both stridor and hoarseness completely resolved 28 days after the onset of palsy: a repeat laryngoscopy study showed normal vocal cord mobility.
Following two consolidation blocks it was decided to administer VCR at full dose (1.5 mg/m2) first, and completely omit the second dose (scheduled just five days later): no side effect was noted. The first reinduction protocol II started 22 days after completion of consolidation block therapy and the four weekly doses of VCR were uneventfully administered with a one-third reduction (1 mg/m2).
After four weeks of interim maintenance the second reinduction protocol II was scheduled and the first weekly dose of VCR was again administered at 1 mg/m2 without any problems; then our patient received glutamic acid 1.5 g daily orally in three divided doses and, one week later, a bolus injection of VCR was administered at full dose. Three days later she developed an intermittent hoarse voice lasting about 72 hours. Moreover, she manifested reduction of deep tendon reflexes, neuritic calf pain (treated with oral acetaminophen) and foot drop; the pain and foot drop resolved after about 24 hours. The following weekly VCR was omitted and glutamic acid was stopped after 10 days of overall treatment. The fourth and last dose of VCR was administered again at 1 mg/m2 and was well tolerated. She is now in complete remission and on maintenance therapy.

Discussion

VCP appears in an early report on the use of VCR, but it seems to be very rare; in a recent review the prevalence among children receiving VCR was 1.36% [1]. Analyzing the literature, we found 18 cases of children with VCR-induced VCP (Table 1) and our patient is the fifth girl reported [19].
Table 1
Literature review of pediatric patients with vincristine induced vocal cord palsy
Authors
Sex/age
Diagnosis
Duration, weeks
Vocal cord palsy
Airway intervention
Swallowing dysfunction
Associated neuropathy
Subsequent vincristine administration
Tobias and Bozeman [2]
M/5 years
ALL
0.5
L
No
No
No
Omitted
F/2 years
NHL-T
2
L
No
No
Yes
Half dose
Annino et al. [3]
M/1.5 years
RMS
6
BL
No
Yes
No
Omitted
M/1.3 years
Ependymoma
2
BL
No
No
No
Omitted
M/3 years
ALL
2
L
No
No
Yes
Half dose
Agarwall et al. [4]
F/11 years
LNH
NA
R
No
No
No
NA
Anghelescu et al. [5]
NA/0.4 years
ALL
1
BL
Yes
Yes
No
NA
Graf et al. [6]
M/15 years
ALL + CMT
34.3
BL
No
No
Yes
NA
Ahmad et al. [7]
M/3 years
ALL + Down’s
38.5
BL
Yes
Yes
No
Omitted
M/1.8 years
Ependymoma
34.3
BL
No
No
No
Omitted
M/2 years
ALL
27
BL
No
Yes
Yes
Omitted*
Kuruvilla et al. [1]
F/1 year
ALL
37
BL
Yes
Yes
No
Omitted
M/4 years
ALL + Down’s
20
BL
Yes
No
Yes
Half dose
M/5 years
ES
7
BL
No
No
No
No indication
M/3 years
RMS
4
L
No
Yes
 
Half dose, then increased to regular regimen
Latiff et al. [8]
M/2 years
ALL
13
BL
No
No
No
Half dose**
F/3 years
ALL
40
BL
Yes***
No
No
Half dose
Naithani et al. [9]
M/14 years
ALL
6
BL
No
Yes
Yes
Omitted
*Vincristine definitely omitted after symptoms recurrence in consequence of drug reintroduction at full dose (drug initially given at 25% of recommended dose and gradually increased to full dose)
**Vincristine definitely omitted after symptoms recurrence in consequence of drug reintroduction at half dose
***Cordectomy.
ALL = acute lymphoblastic leukemia; BL = bilateral; CMT = Charcot Marie Tooth; Down’s = Down’s syndrome; ES = Ewing’s sarcoma; L = left; NA = not assessed; NHL-T = T cell non-Hodgkin’s lymphoma; R = right; RMS = rhabdomyosarcoma
Most cases are seen in younger children, with cases also reported in babies [5]; the median age is 2.7 years and 12 out of 18 patients were less than three years of age. The paralysis can be bilateral or, in about one-quarter of cases, unilateral, with the left vocal cord seemingly much more commonly affected (four cases versus one case of right VCP). Swallowing problems are fairly common (about one-third of the patients) and, apparently only when the paralysis is bilateral, a period of mechanical ventilation may be required. Remarkably, assisted ventilation was necessary only in five out of 18 patients [1, 5, 7, 8]. It is fairly certain that Down’s syndrome patients are at higher risk of airway intervention (two out of two reported cases) [1, 7]. The laryngeal dysfunction can be isolated or associated, as in about one-third of patients, with other manifestations of neurotoxicity, but never with other cranial neuropathies [13, 6, 7, 9]. The problem resolves in a period of one to 10 months, usually with stridor resolving before the hoarseness. The median duration is six weeks.
The role of glutamic acid in decreasing VCR-induced neurotoxicity has been analyzed in some studies. Recently, a trial in a pediatric population [10] supported the efficacy of glutamic acid in preventing the neurological side effects of VCR via a mechanism that remains to be elucidated, but, to the best of our knowledge, it has never been used after first occurrence of neurotoxicity. In our patient glutamic acid, as rescue treatment, proved to be ineffective and when a full dose of VCR was given one week after a reduced dose, our patient showed not only a reappearance of stridor and hoarseness but also a transient peripheral neuropathy. On reviewing pediatric cases, reintroduction of VCR at half dose was associated with a recurrence of palsy in only one case out of six [8], and no respiratory failure developed. In contrast, besides our patient, there are only another two cases reported of VCR reintroduction at full dose [1, 7], and in one of them there was a relapse [7].

Conclusions

In our opinion the administration of weekly VCR at half to two-thirds dose should be the recommended initial approach after a case of drug-induced vocal cord palsy. We have not found evidence that administration of glutamic acid can prevent relapse of VCP.

Consent

Written informed consent was obtained from the parents of the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Acknowledgments

The authors wish to thank Professor Frank Adamo for the language support in revising the manuscript, and the Parents’ Association “A.S.L.T.I.-Liberi di Crescere” Onlus for financial support.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

PF made substantial contributions to the structure of the manuscript, was involved in clinical management of our patient and drafted the manuscript. ST was involved in clinical management and helped draft the manuscript. SC and GB analyzed and interpreted patient data regarding disease. GO was involved in pharmaceutical management of the disease, and participated in drafting part of the manuscript. PD made substantial contributions to the structure of the manuscript, was involved in clinical management of our patient, and was a major contributor in writing the manuscript. All authors read and approved the final manuscript.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Jetzt e.Med zum Sonderpreis bestellen!

e.Med Allgemeinmedizin

Kombi-Abonnement

Mit e.Med Allgemeinmedizin erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der allgemeinmedizinischen Zeitschriften, inklusive einer gedruckten Allgemeinmedizin-Zeitschrift Ihrer Wahl.​​​​​​​

Jetzt e.Med zum Sonderpreis bestellen!​​​​​​​

Zusatzmaterial
Authors’ original file for figure 1
13256_2011_2101_MOESM1_ESM.pdf
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2012

Journal of Medical Case Reports 1/2012 Zur Ausgabe